series-b
Stage
1
Investors
About
Develops the Reprieve System, an intelligent personalized decongestion management solution for patients with acute decompensated heart failure to optimize fluid removal and clinical outcomes. The company is developing a medical device-backed therapy evaluated in randomized clinical trials (FASTR pilot).
Explore Reprieve Cardiovascular's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.